Bispecific antibodies and uses thereof
This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.
1. An antibody or an antigen-binding fragment thereof that binds to CD20 and CD3, comprising
a first polypeptide comprising a first heavy chain variable region (VH1) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH1 CDR1 region comprises the amino acid sequence of SEQ ID NO: 16, the VH1 CDR2 region comprises the amino acid sequence of SEQ ID NO: 17, and the VH1 CDR3 region comprises the amino acid sequence of SEQ ID NO: 18;
a second polypeptide comprising a second heavy chain variable region (VH2) comprising CDRs 1, 2, and 3, wherein the VH2 CDR1 region comprises the amino acid sequence of SEQ ID NO: 22, the VH2 CDR2 region comprises the amino acid sequence of SEQ ID NO: 23, and the VH2 CDR3 region comprises the amino acid sequence of SEQ ID NO: 24;
a third polypeptide comprising a first light chain variable region (VL1) comprising CDRs 1, 2, and 3, wherein the VL1 CDR1 region comprises the amino acid sequence of SEQ ID NO: 28, the VL1 CDR2 region comprises the amino acid sequence of SEQ ID NO: 29, and the VL1 CDR3 region comprises the amino acid sequence of SEQ ID NO: 30; and
a fourth polypeptide comprising a second light chain variable region (VL2) comprising CDRs 1, 2, and 3, wherein the VL2 CDR1 region comprises the amino acid sequence of SEQ ID NO: 28, the VL2 CDR2 region comprises the amino acid sequence of SEQ ID NO: 29, and the VL2 CDR3 region comprises the amino acid sequence of SEQ ID NO: 30;
wherein
the VH1 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 3.
2. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises the amino acid sequence of SEQ ID NO: 1;
the VH2 comprises the amino acid sequence of SEQ ID NO: 2;
the VL1 comprises the amino acid sequence of SEQ ID NO: 3; and
the VL2 comprises the amino acid sequence of SEQ ID NO: 3.
3. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the first polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 40.
4. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the first polypeptide comprises the amino acid sequence of SEQ ID NO: 35; and
the second polypeptide comprises the amino acid sequence of SEQ ID NO: 38.
5. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is a bispecific antibody or antigen-binding fragment thereof.
6. An antibody or an antigen-binding fragment thereof that binds to CD20 and CD3 comprising
a first heavy chain variable region (VH1) comprising CDR1, CDR2, and CDR3, wherein the VH1 CDR1, VH1 CDR2, and VH1 CDR3 are identical to CDR1, CDR2, and CDR3 of SEQ ID NO: 1;
a second heavy chain variable region (VH2) comprising CDR1, CDR2, and CDR3, wherein the VH2 CDR1, VH2 CDR2, and VH2 CDR3 are identical to CDR1, CDR2, and CDR3 of SEQ ID NO: 2;
a first light chain variable region (VL1) comprising CDR1, CDR2, and CDR3, wherein the VL1 CDR1, VL1 CDR2, and VL1 CDR3 are identical to CDR1, CDR2, and CDR3 of SEQ ID NO: 3; and
a second light chain variable region (VL2) comprising CDR1, CDR2, and CDR3, wherein the VL2 CDR1, VL2 CDR2, and VL2 CDR3 are identical to CDR1, CDR2, and CDR3 of SEQ ID NO: 3, wherein
the VH1 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 3.
7. An antibody or an antigen-binding fragment thereof that binds to CD20 and CD3 comprising
a first heavy chain variable region (VH1) comprising the amino acid sequence of SEQ ID NO: 1;
a second heavy chain variable region (VH2) comprising the amino acid sequence of SEQ ID NO: 2;
a first light chain variable region (VL1) comprising the amino acid sequence of SEQ ID NO: 3; and
a second light chain variable region (VL2) comprising the amino acid sequence of SEQ ID NO: 3.
8. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 3.
9. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 3.
10. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 3.
11. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 3.
12. The antibody or the antigen-binding fragment thereof of claim 1 , wherein
the VH1 comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 1;
the VH2 comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 2;
the VL1 comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 3; and
the VL2 comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 3.
13. The antibody or the antigen-binding fragment thereof of claim 3 , wherein
the first polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 40.
14. The antibody or the antigen-binding fragment thereof of claim 3 , wherein
the first polypeptide comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 96% identical to SEQ ID NO: 40.
15. The antibody or the antigen-binding fragment thereof of claim 3 , wherein
the first polypeptide comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 97% identical to SEQ ID NO: 40.
16. The antibody or the antigen-binding fragment thereof of claim 3 , wherein
the first polypeptide comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 40.
17. The antibody or the antigen-binding fragment thereof of claim 3 , wherein
the first polypeptide comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 34, 35, or 36;
the second polypeptide comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 37, 38, or 39;
the third polypeptide comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 40; and
the fourth polypeptide comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 40.
18. The antibody or the antigen-binding fragment thereof of claim 1 ,
wherein the VH1 and the VL1 associate with each other, forming a first antigen binding region that specifically binds to CD20, and the VH2 and the VL2 associate with each other, forming a second antigen binding region that specifically binds to CD3,
wherein the binding affinity, as measured by association constant Ka, of the first antigen binding region when it binds to CD20 is at least 100 times greater than the binding affinity of the second antigen binding region when it binds to CD3, wherein the VL1 and the VL2 are identical.
19. The antibody or the antigen-binding fragment thereof of claim 18 ,
wherein the binding affinity of the first antigen binding region when it binds to CD20 is at least 1000 times greater than the binding affinity of the second antigen binding region when it binds to CD3.
20. The antibody or the antigen-binding fragment thereof of claim 18 ,
wherein the first antigen binding region specifically binds to CD20 with a binding affinity, as measured by association constant Ka, that is greater than 10 8 M −1 .
21. The antibody or the antigen-binding fragment thereof of claim 18 ,
wherein the second antigen binding region specifically binds to CD3 with a binding affinity, as measured by association constant Ka, that is less than 10 6 M −1 .
22. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof has a functional Fc region that can induce antibody-dependent cellular cytotoxicity (ADCC).
23. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the first polypeptide and the second polypeptide associate with each other by the knobs into holes approach.